Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Busy address KBO
39 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
PI PHARMA from Sint-Pieters-Leeuw, company number BE0883315652, closed financial year 2025 with a result of € 174,639 after tax. For that financial year PI PHARMA recorded revenue of € 56.4 million and equity of € -161,750. Compared with financial year 2024, the result moved from € 26,306 to € 174,639. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 25, 2026.
€ -161,750
▲ € 174,639 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 174,639
▲ € 148,333 vs 2024
Profit after tax over the fiscal year.
€ 349,739
▼ 72% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -1 million.
People and assets in 2025
11.6
▲ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.3 million
▲ 2% vs 2024
€ 107,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 8.2 million
▲ 155% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 57 days on average.
€ 3.2 million
▲ 68% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 37,720,096 | € 35,591,068 | € 40,057,635 | € 56,377,098 | ▲ 41% |
| Profit after taxes | € -84,523 | € 125,470 | € 26,306 | € 174,639 | ▲ € 148,333 |
| Equity | € -488,165 | € -362,694 | € -336,389 | € -161,750 | ▲ € 174,639 |
| Total debts | € 6,561,404 | € 4,692,733 | € 5,151,887 | € 13,364,002 | ▲ 159% |
| Cash | € 2,313,020 | € 1,172,100 | € 1,242,372 | € 349,739 | ▼ 72% |
| Retained profit | € -1,350,665 | € -1,225,194 | € -1,198,889 | € -1,024,250 | ▲ € 174,639 |
| Balance sheet total | € 6,073,240 | € 4,330,039 | € 4,815,498 | € 13,202,253 | ▲ 174% |
| Employees (FTE) | 11.4 | 10.7 | 11.4 | 11.6 | ▲ 0.2 |
Key figures of PI PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PI PHARMA?
What happened at PI PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Nikka Management BV stepped down as director. NBB
- Jordan Chir stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 174,639 (▲ € 148,333 vs 2024). Source: NBB ↗
- Jordan Chir became a director. NBB
- LMDC GmbH stepped down as director. NBB
- Nikka Management BV became a director. NBB
- LMDC GmbH became a director. NBB
- New establishment in Anderlecht. KBO
In short
From € 84,523 loss in 2022 to € 174,639 profit in 2025.
Paid € 209,247 in corporate taxes since 2022.
Best year ever: 2025, with € 174,639 profit.
Pays suppliers within 57 days on average.
A new publication or filing at PI PHARMA? We notify you, reason included.
Follow PI PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of MEDIGROUP comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PI PHARMAThe shares are held by MEDIGROUP (100%).
Directors
According to the 2025 annual accounts
since 2025 · until 2031
since 2025 · until 2031
LMDC GmbH
Director · represented by Libor Matyasek
Also active at: ECOPHARMASUPPLY DISTRIBUTION, IMPEXECO, ECO.PHARMA.SUPPLY, MEDIGROUP
since 2025 · until 2025
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Bergensesteenweg 709
1600 Sint-Pieters-Leeuw
Marie Curiesquare 50
1070 Anderlecht
Active since 1 January 2011
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 39 companies are registered at this address.
All companies at this address →SURUBI
€ 15,011 gross margin · 2025
IMMO PRIMERA
€ 324,993 gross margin · 2025
IBURU
€ 132,863 gross margin · 2025
Bedrijvencentrum Zennevallei
€ 217,792 gross margin · 2025
GALLÉ
€ -5,836 gross margin · 2025
+34 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0883.315.652
- VAT number
- BE 0883.315.652
- Registered office
- Bergensesteenweg 709, 1600 Sint-Pieters-Leeuw
- Names & denominations
- PI PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 5 September 2006
- Peppol
- Active · Active since 6 Jan 2026
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren